Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.64 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21499186 | 1.00 | SIGMAR1 (0.64) | SIGMAR1TMEM97KDM4EALDH1A1GAA | |
| SCHEMBL16408519 | 1.00 | SIGMAR1 (0.64) | SIGMAR1TMEM97KDM4EALDH1A1GAA | |
| SCHEMBL21499181 | 0.88 | SIGMAR1 (0.80) | SIGMAR1TMEM97KDM4EALDH1A1GAA | |
| SCHEMBL16408534 | 0.88 | SIGMAR1 (0.80) | SIGMAR1TMEM97KDM4EALDH1A1GAA | |
| SCHEMBL16408629 | 0.88 | SIGMAR1 (0.80) | SIGMAR1TMEM97KDM4EALDH1A1GAA | |
| SCHEMBL16408549 | 0.81 | SIGMAR1 (0.68) | SIGMAR1TMEM97KDM4EALDH1A1GAA | |
| SCHEMBL18099330 | 0.78 | SIGMAR1 (1.00) | SIGMAR1TMEM97HRH3 | |
| SCHEMBL21871135 | 0.75 | SIGMAR1 (0.64) | SIGMAR1TMEM97 | |
| SCHEMBL16408639 | 0.75 | SIGMAR1 (0.64) | SIGMAR1TMEM97 | |
| SCHEMBL16408520 | 0.75 | SIGMAR1 (0.64) | SIGMAR1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450275-B2 | Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450275-B2 | Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain | ELAVL1, ADH1A, NGF | SIGMAR1 423/4885TMEM97 1532/4885KDM4E 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.